Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2006-05-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis C
NCT00755742
Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy
NCT00188240
Epidemiology of Chronic Hepatitis C and Disease Modelling
NCT03566563
High Dose Insulin Therapy to Improve Liver Function
NCT01271140
Metformin Therapy in HCV Infection
NCT02972723
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hepatitis C subjects
Due to start therapy for Hepatitis C
No interventions assigned to this group
Controls
Healthy males
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 25-55 years
* Chronic Hepatitis C (PCR positive) and fibrosis ≤ F2 (if liver biopsy done)
* Genotypes 1 or 3
* Due to commence antiviral therapy
* BMI \< 30
Exclusion Criteria
* \> 20 g ETOH per day
* Type 2 Diabetes (need an OGTT if fasting BGL\> 5.7)
* Concurrent HIV
* Other cause of liver disease
25 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Garvan Institute of Medical Research
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Jerry Greenfield
Head of Endocrinology Department St Vincent's Hospital Sydney
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Donald Chisholm, MBBS, FRACP
Role: PRINCIPAL_INVESTIGATOR
Garvan Institute of Medical Research
Jacob George, MBBS, FRACP
Role: PRINCIPAL_INVESTIGATOR
Storr Liver Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Garvan Institute Of Medical Research
Sydney, New South Wales, Australia
Storr Liver Unit
Sydney, New South Wales, Australia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Milner KL, van der Poorten D, Trenell M, Jenkins AB, Xu A, Smythe G, Dore GJ, Zekry A, Weltman M, Fragomeli V, George J, Chisholm DJ. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology. 2010 Mar;138(3):932-41.e1-3. doi: 10.1053/j.gastro.2009.11.050. Epub 2009 Dec 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H04/126
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.